Atea Pharmaceuticals, Inc.
AVIR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $351,367 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $83,367 | $70,090 | $62,390 | $167,205 |
| Gross Profit | -$83,367 | -$70,090 | -$62,390 | $184,162 |
| % Margin | – | – | – | 52.4% |
| R&D Expenses | $145,401 | $132,843 | $88,836 | $167,205 |
| G&A Expenses | $48,849 | $49,919 | $48,714 | $45,785 |
| SG&A Expenses | $48,849 | $49,919 | $48,714 | $45,785 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$84,667 | -$88,690 | -$69,290 | -$167,205 |
| Operating Expenses | $109,583 | $94,072 | $68,260 | $45,785 |
| Operating Income | -$192,950 | -$164,162 | -$130,650 | $138,377 |
| % Margin | – | – | – | 39.4% |
| Other Income/Exp. Net | $25,490 | $29,224 | $11,151 | $213 |
| Pre-Tax Income | -$167,460 | -$134,938 | -$119,499 | $138,590 |
| Tax Expense | $925 | $1,018 | -$3,590 | $17,400 |
| Net Income | -$168,385 | -$135,956 | -$115,909 | $121,190 |
| % Margin | – | – | – | 34.5% |
| EPS | -2 | -1.63 | -1.39 | 1.46 |
| % Growth | -22.7% | -17.3% | -195.2% | – |
| EPS Diluted | -2 | -1.63 | -1.39 | 1.37 |
| Weighted Avg Shares Out | 84,265 | 83,390 | 83,245 | 82,820 |
| Weighted Avg Shares Out Dil | 84,265 | 83,390 | 83,245 | 88,249 |
| Supplemental Information | – | – | – | – |
| Interest Income | $25,490 | $29,224 | $11,151 | $213 |
| Interest Expense | $0 | $0 | $11,151 | $0 |
| Depreciation & Amortization | $416 | $416 | $260 | $29 |
| EBITDA | -$131,800 | -$119,593 | -$110,844 | $138,406 |
| % Margin | – | – | – | 39.4% |